Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: GB002 (platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, c-KIT inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (hypoxia-inducible factor), which is for the treatment of inflammatory bowel disease; GB1275 (CD11b modulator), which is for the treatment of oncology indications; and GB001 (prostaglandin D2 receptor 2), which is for the treatment of eosinophilic asthma and other allergic conditions. The GOSS stock yearly return is shown above.
The yearly return on the GOSS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GOSS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|